Mostra i principali dati dell'item
Assessment of reporting quality of meta-analyses of randomized controlled trials in neovascular age-related macular degeneration published from April 2014 to May 2018 using prisma statement
dc.creator | Tounakaki O., Tsakou Α., Malamas A., Chrisoula D., Ioannis S., Elias Z. | en |
dc.date.accessioned | 2023-01-31T10:09:17Z | |
dc.date.available | 2023-01-31T10:09:17Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.1007/s10792-019-01282-7 | |
dc.identifier.issn | 01655701 | |
dc.identifier.uri | http://hdl.handle.net/11615/79745 | |
dc.description.abstract | Purpose: To evaluate the reporting quality of meta-analysis on neovascular age-related macular degeneration treatment and safety profile based on PRISMA statement. Methods: Electronic search performed in August 2018 to retrieve meta-analyses published from April 2014 to May 2018. PRISMA evaluation was determined by total scores of individual meta-analyses and items scores. Statistical analysis of parameters affecting the reporting evaluation included subgroup multivariate analysis and regression analysis. Results: Twelve meta-analyses were finally included, three being Cochrane systematic reviews. Mean PRISMA score is 23.2/27 (86.1%). Eleven PRISMA ITEMS had significantly higher %score in 12 meta-analyses than in nine non-Cochrane meta-analyses measurements. Positive strong correlation identified between PRISMA %score and journal impact factor (JIF). Multivariate analysis between high-scored and low-scored meta-analyses established difference in means of several parameters (JIF, Publication Year). Conclusions: The evaluation of overall reporting quality was favorable. As expected, the key role of several characteristics of meta-analysis affects this quality. Under-reporting of specific items (protocol, search strategy and assessment of risk of bias) indicates the urgency for PRISMA compliance. © 2020, Springer Nature B.V. | en |
dc.language.iso | en | en |
dc.source | International Ophthalmology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077617684&doi=10.1007%2fs10792-019-01282-7&partnerID=40&md5=e42fb2568821676994d3f3415c0e2133 | |
dc.subject | Article | en |
dc.subject | clinical evaluation | en |
dc.subject | correlational study | en |
dc.subject | data analysis software | en |
dc.subject | electronic health record | en |
dc.subject | human | en |
dc.subject | meta analysis (topic) | en |
dc.subject | Preferred Reporting Items for Systematic Reviews and Meta-Analyses | en |
dc.subject | quality control | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | systematic review | en |
dc.subject | wet macular degeneration | en |
dc.subject | disease management | en |
dc.subject | meta analysis | en |
dc.subject | total quality management | en |
dc.subject | wet macular degeneration | en |
dc.subject | Disease Management | en |
dc.subject | Humans | en |
dc.subject | Quality Improvement | en |
dc.subject | Randomized Controlled Trials as Topic | en |
dc.subject | Wet Macular Degeneration | en |
dc.subject | Springer | en |
dc.title | Assessment of reporting quality of meta-analyses of randomized controlled trials in neovascular age-related macular degeneration published from April 2014 to May 2018 using prisma statement | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |